ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+25.8%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$168M
AUM Growth
+$168M
(+97%)
Cap. Flow
+$26.7M
Cap. Flow
% of AUM
15.89%
Top 10 Holdings %
Top 10 Hldgs %
72.94%
Holding
26
New
7
Increased
6
Reduced
7
Closed
4
Top Buys
| 1 |
argenx
ARGX
|
$13.3M |
| 2 |
Soleno Therapeutics
SLNO
|
$12.5M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$11.6M |
| 4 |
Olema Pharmaceuticals
OLMA
|
$9.25M |
| 5 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$6.81M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$22M |
| 2 |
Cytokinetics
CYTK
|
$6.58M |
| 3 |
Ardelyx
ARDX
|
$3.6M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$3.06M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$2.41M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Jasper Therapeutics
JSPR
$45.5M
| $28.9M | 17.2% | 3,659,255 +515,091 | +16% | +$4.06M |
|
|
2
argenx
ARGX
$43.6B
| $13.3M | 7.93% | +35,000 | New | +$13.3M |
|
|
3
Soleno Therapeutics
SLNO
$3.6B
| $12.5M | 7.43% | +309,950 | New | +$12.5M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $11.6M | 6.9% | +489,938 | New | +$11.6M |
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $11.1M | 6.64% | 241,961 -25,000 | -9% | -$1.15M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.1M | 6.03% | 141,348 -33,652 | -19% | -$2.41M |
|
|
7
Olema Pharmaceuticals
OLMA
$375M
| $9.25M | 5.51% | +659,035 | New | +$9.25M |
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $8.98M | 5.35% | 150,000 -31,805 | -17% | -$1.9M |
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $8.66M | 5.16% | 143,479 -39,626 | -22% | -$2.39M |
|
10
Axsome Therapeutics
AXSM
$6.05B
| $8.03M | 4.78% | 100,862 -9,738 | -9% | -$775K |
|
11
Merus
MRUS
$4.98B
| $7.56M | 4.5% | 274,923 +53,539 | +24% | +$1.47M |
|
|
ALPN
12
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $6.81M | 4.06% | +357,271 | New | +$6.81M |
|
13
Geron
GERN
$893M
| $6.27M | 3.74% | 2,971,639 +750,000 | +34% | +$1.58M |
|
|
AMAM
14
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $5.49M | 3.27% | 385,383 +104,294 | +37% | +$1.49M |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $4.9M | 2.92% | +347,036 | New | +$4.9M |
|
|
HARP
16
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $4.87M | 2.9% | +428,400 | New | +$4.87M |
|
17
Amylyx Pharmaceuticals
AMLX
$836M
| $4.06M | 2.42% | 275,773 +3,083 | +1% | +$45.4K |
|
|
18
Praxis Precision Medicines
PRAX
$958M
| $1.57M | 0.93% | 70,424 -985,946 | -93% | -$22M |
|
19
Compass Therapeutics
CMPX
$483M
| $1.3M | 0.78% | 834,630 -80,000 | -9% | -$125K |
|
20
ProMIS Neurosciences
PMN
$28M
| $1.23M | 0.73% | 1,066,674 +534,759 | +101% | +$615K |
|
21
Context Therapeutics
CNTX
$75.4M
| $820K | 0.49% | 725,951 | – | – |
|
|
MDVL
22
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $529K | 0.32% | 117,897 | – | – |
|
|
23
Ardelyx
ARDX
$1.53B
| – | – | -881,356 | Closed | -$3.6M |
|
24
Black Diamond Therapeutics
BDTX
$157M
| – | – | -634,191 | Closed | -$1.82M |
|
|
25
Cytokinetics
CYTK
$4.23B
| – | – | -223,382 | Closed | -$6.58M |
|